Subscribe for the Newsletter

Mobile Navigation

The Next Generation of Diabetes Cell Replacement Therapies

The Next Generation of Diabetes Cell Replacement Therapies

Nov 18, 2026PAO-11-26-PA-09

Key Takeaways

  • Stem-cell–derived islet therapies are demonstrating the potential to restore endogenous insulin secretion in people with type 1 diabetes, with early clinical results showing insulin independence in some patients.

  • Immune rejection remains a major obstacle to broader use of islet cell replacement therapies, driving development of encapsulation technologies and gene-edited, immune-evasive cells that could reduce dependence on systemic immunosuppression.

  • Scalable manufacturing of stem-cell–derived islets requires precise control over differentiation, cellular composition, functional maturity, and batch-to-batch consistency, even as bioreactor technologies improve production yields.

  • Potency testing and quality control strategies must establish that manufactured islet cells retain glucose-responsive insulin secretion and other critical characteristics throughout production, preservation, and delivery.

  • The future of diabetes cell replacement therapies will depend on combining durable clinical efficacy, effective immune protection, reproducible manufacturing, and reliable product distribution to enable broader patient access.

The Promise and Limitations of Islet Cell Replacement

For people with type 1 diabetes, maintaining blood glucose control requires lifelong replacement of insulin that the pancreas can no longer produce. Insulin injections and infusion pumps supply the hormone needed to regulate glucose levels, while continuous glucose monitors and automated insulin delivery systems have made that process increasingly sophisticated. Even advanced systems must approximate the work of healthy pancreatic islets, which sense changes in blood glucose and adjust insulin secretion in response. The possibility of restoring that biological function has long motivated research into pancreatic islet transplantation.

Cell replacement therapies seek to establish a living population of insulin-producing cells capable of responding to the body's changing metabolic needs. Transplantation of pancreatic islets obtained from deceased donors has demonstrated the feasibility of this approach, but donor tissue availability and the need for immunosuppression have limited its broader application. Advances in stem-cell differentiation are creating opportunities to produce functional islet cells from renewable starting materials, potentially overcoming a fundamental constraint on the supply of transplantable cells.

Recent clinical findings suggest that this approach is beginning to deliver meaningful results. In a phase I/II study of zimislecel, an allogeneic stem-cell–derived islet therapy developed by Vertex Pharmaceuticals, 10 of 12 participants who received the full dose were insulin-independent at day 365. All 12 were free of severe hypoglycemic events during the assessment period and achieved glycated hemoglobin levels below 7%. Although the study was small and the analyses were interim and not prespecified, the results demonstrated that transplanted stem-cell-derived islets could restore clinically meaningful insulin production in patients who previously had no detectable endogenous secretion.1

The regulatory foundation for islet replacement was established in 2023, when the U.S. Food and Drug Administration (FDA) approved Lantidra (donislecel-jujn), an allogeneic pancreatic islet therapy derived from deceased donors, for certain adults with type 1 diabetes who experience recurrent severe hypoglycemia despite intensive diabetes management.2 The approval demonstrated that cellular restoration of insulin secretion could achieve regulatory acceptance for a defined patient population. Stem-cell-derived products build on that therapeutic principle while introducing a different approach to obtaining and manufacturing the cells.

The clinical promise is substantial, but achieving insulin independence does not necessarily eliminate the burdens associated with transplantation. Participants in the zimislecel study received immunosuppressive therapy, and Lantidra also requires immunosuppression to maintain transplanted cell viability. The next generation of therapies must address that limitation while establishing reliable ways to produce and deliver functional cells. The biological responsiveness that makes living cells attractive as treatments also complicates their protection, characterization, preservation, and manufacture.

Producing Cells That Function Like Human Islets

Developing a stem-cell-derived islet therapy begins with reproducing key stages of pancreatic development under controlled manufacturing conditions. Pluripotent stem cells can give rise to many different cell types, but generating a therapeutically useful islet population requires guiding them through a sequence of developmental stages. Directed differentiation protocols establish progressively more specialized populations, including pancreatic progenitors and endocrine cells, ultimately producing aggregates containing insulin-secreting beta cells and other islet-associated cell types.3

Induced pluripotent stem cells (iPSCs), generated by reprogramming differentiated cells into a pluripotent state, provide one possible starting material. Their capacity for expansion creates opportunities to produce substantial quantities of therapeutic cells, but the differentiation process must be controlled carefully. Cells can progress through developmental stages at different rates or adopt unintended identities, producing populations that contain both desired endocrine cells and other cell types.3

A study by Verhoeff and colleagues illustrates this complexity.4 The investigators developed a bioreactor-based differentiation process that generated cells expressing pancreatic progenitor and islet-associated markers, but they also identified SOX9-positive ductal cells and SLC18A1-positive enterochromaffin cells. Examination of transplanted grafts revealed mature islet-like cells alongside persistent ductal tissue. The findings demonstrate that successful generation of pancreatic endocrine populations can coexist with substantial cellular heterogeneity.

Some cellular diversity is desirable. Native pancreatic islets contain several endocrine cell populations, including insulin-producing beta cells, glucagon-producing alpha cells, and somatostatin-producing delta cells, whose coordinated activity contributes to glucose regulation. The challenge is distinguishing appropriate cellular complexity from unwanted or incompletely differentiated populations that could compromise product performance or safety. Residual pluripotent cells are particularly concerning because they can contribute to unwanted tissue formation after transplantation. Genomic instability acquired during expansion or differentiation creates additional safety risks.

Functional maturity presents a related challenge. A 2026 review comparing stem-cell–derived and primary human beta cells describes differences in metabolic coupling, calcium signaling, and insulin granule handling, including limitations in glucose responsiveness observed in vitro.5 These findings help explain why expression of insulin or characteristic cellular markers alone cannot establish therapeutic suitability. Developers must determine whether the cells respond appropriately to changing glucose concentrations and maintain that response after transplantation.

In the zimislecel study, C-peptide was undetectable before treatment in all 14 participants included in the interim analysis but became detectable following transplantation, providing evidence of engraftment and endogenous insulin secretion. Improvements in glycemic control demonstrated that the cells could produce a meaningful physiological effect, although longer follow-up is needed to establish durability.

Protecting Transplanted Cells Without Sacrificing Function

After transplantation, functional islet cells must survive within an immune environment that can threaten their continued activity. In type 1 diabetes, two related mechanisms are relevant: the autoimmune response responsible for destruction of the patient's original beta cells and the immune response against transplanted cells obtained from another individual. Allogeneic rejection and recurrent autoimmunity involve different forms of immune recognition, and protection strategies must account for the relevant mechanisms.

Systemic immunosuppression remains an established means of supporting allogeneic islet survival. It allows transplanted cells to interact directly with their surrounding environment but exposes patients to risks that may be difficult to justify outside populations with particularly severe disease. The FDA's assessment of Lantidra identified serious adverse reactions associated with the transplantation procedure and the immunosuppressive medications required to maintain cell viability.2 The zimislecel study likewise reported serious adverse events, with neutropenia occurring in three participants, and two deaths.1 One death was caused by cryptococcal meningitis, and the other by severe dementia with agitation associated with progression of preexisting neurocognitive impairment. These findings underscore the importance of evaluating the safety of the complete treatment regimen without assuming that every adverse event was directly caused by the cellular product.

Encapsulation seeks to reduce dependence on systemic immunosuppression by physically separating transplanted cells from damaging immune interactions. Protective biomaterials can surround individual cell aggregates or larger collections of cells, potentially restricting immune access while allowing essential molecular exchange. The difficulty is maintaining sufficient permeability for oxygen and nutrient delivery, glucose sensing, and insulin release without compromising the protective function of the barrier.

Macroencapsulation devices contain relatively large cell populations within structures that may facilitate stability and retrieval, but their configuration can limit oxygenation and nutrient transport. Microencapsulation distributes smaller cell populations among individual protective structures, potentially improving molecular exchange while introducing challenges involving inflammatory responses, fibrosis, and retrieval. Open scaffolds can facilitate vascularization and interaction with surrounding tissue, although they do not inherently provide immune isolation. Each configuration presents a different balance among cell survival, immune protection, and physiological responsiveness.

The clinical experience with Vertex's VX-264 program illustrates the difficulty of balancing these requirements.6 The encapsulated islet-cell therapy was designed to provide immune protection without systemic immunosuppression, but Vertex discontinued further clinical development after the treatment failed to demonstrate sufficient increases in C-peptide to deliver the intended clinical benefit. Although the company reported that the treatment was generally safe and well tolerated, the efficacy results were insufficient to support continued development.

The outcome does not establish that encapsulation is inherently ineffective. It demonstrates that a protective device must support adequate therapeutic function under clinical conditions. The performance of the complete implanted system, including its cellular component, biomaterials, and interaction with surrounding tissue, determines whether the approach can provide clinically meaningful insulin secretion.

Genetic engineering offers another strategy by modifying transplanted cells to reduce immune recognition. Rather than physically isolating the cells, this approach seeks to alter the cellular characteristics that trigger immune rejection. It could potentially permit more direct interaction with surrounding tissue while reducing the need for systemic immunosuppression, although immune protection and long-term safety must be demonstrated for each engineered product.3

In 2025, Carlsson and colleagues reported transplantation of genetically modified allogeneic donor islets into the forearm muscle of a man with longstanding type 1 diabetes.7 The investigators used gene editing and lentiviral modification to create cells intended to evade immune rejection. The patient received no immunosuppressive medication, and measurements at 12 weeks demonstrated glucose-responsive insulin secretion without evidence of an immune response against the transplanted cells in the assessments reported.

A subsequent report extended the observations to 14 months, with evidence supporting continued beta-cell function and a lack of immune response against the graft in the reported assessments.8 These findings are encouraging because they demonstrate the possibility of transplanted islet function without systemic immunosuppression. However, the observations involve a single patient and do not establish broader clinical efficacy, complete immune invisibility, or long-term durability.

The distinction between donor-derived and stem-cell-derived products is important. The clinical findings involved genetically modified donor islets, whereas applying similar immune-evasion strategies to stem-cell-derived products would require integrating genetic modification with cell expansion and differentiation. Developers would need to demonstrate that the engineered cells retain appropriate endocrine function while addressing potential safety concerns associated with the modifications and resulting cellular population.

Encapsulation and genetic modification therefore present different development tradeoffs. The former introduces biomaterial and device-related requirements that must be balanced against cellular function, while the latter adds another dimension to cellular characterization and safety assessment. Their relative advantages will depend on the performance of the complete therapeutic product.

Scaling Islet Production While Preserving Quality

The ability to generate functional islet cells from renewable starting materials creates an opportunity to expand production beyond the limitations of deceased-donor tissue. Realizing that potential requires processes capable of delivering consistent cellular populations with appropriate composition, functional maturity, and safety characteristics. The central manufacturing challenge is maintaining control over a complex biological differentiation process as production volumes increase.

Conventional planar culture methods have provided a foundation for developing stem-cell differentiation protocols, but their reliance on extensive culture surfaces can constrain production efficiency. Suspension bioreactors offer an alternative by allowing cells to expand and differentiate in three-dimensional environments. These systems can increase production within a defined culture volume, although their advantages depend on maintaining conditions that support reproducible differentiation and functional performance.4

Verhoeff and colleagues demonstrated the potential benefits of suspension manufacturing in their study comparing semi-planar differentiation with a bioreactor-based process for human iPSCs.4 The semi-planar approach produced approximately 8.3 million cells, while differentiation in a 100-mL Vertical-Wheel bioreactor generated approximately 105 million cells. The investigators also reported an 88.8% reduction in process costs under the conditions evaluated. These findings demonstrate that changing the culture configuration can substantially improve production efficiency within a defined experimental system.

The cost reduction is noteworthy, but it reflects the specific comparison performed by the investigators and should not be extrapolated to commercial cost of goods. Manufacturing economics will also depend on process reproducibility, the quantity of acceptable therapeutic material recovered, the resources required for quality testing, and the additional operations needed to prepare the final product.

A separate study by Dadheech and colleagues investigated the scale-up of human iPSC-derived islet production using Vertical-Wheel bioreactors.8 Increasing reactor volume from 0.1 to 0.5 L increased islet-equivalent yield from 15,005 to 183,002, representing approximately a 12-fold increase. The resulting cells demonstrated glucose-responsive insulin secretion, and transplantation reversed diabetes in a chemically induced mouse model. These findings suggest that increased production volume can be compatible with retention of important functional characteristics under the tested conditions.

The two studies address different aspects of manufacturing development. Verhoeff and colleagues demonstrated improvements in production yield and process-specific costs, while Dadheech and colleagues evaluated increased bioreactor volume alongside structural and functional characteristics of the resulting islets. Their production endpoints differ, so the results cannot establish a direct comparison of manufacturing efficiency.

Further scale-up introduces challenges involving the physical environment of the culture system. Stem-cell-derived islets develop as multicellular aggregates, and their characteristics can be influenced by culture conditions and the way cells are maintained in suspension. The Dadheech study identifies scalability, cell loss, and batch-to-batch consistency among the challenges associated with developing these processes.9 Its findings support the importance of controlling aggregate formation and maintaining product characteristics as reactor volume increases.

Controlling these variables requires a detailed understanding of the successive differentiation stages. The starting cell population must possess appropriate characteristics, and the process must guide cells through the intended developmental transitions while limiting unwanted populations. Stage-specific characterization can help developers establish relationships between process conditions and cellular outcomes, providing a basis for identifying critical process parameters and maintaining consistency.

Starting materials introduce additional considerations. The generation of iPSCs through cellular reprogramming adds a manufacturing stage that requires its own characterization and controls. Cell banks must be evaluated for appropriate identity, genomic stability, and other quality characteristics before they can provide a reliable foundation for downstream differentiation. The quality of ancillary materials, including growth factors and other process inputs, also requires attention because their variability or persistence in the finished product can affect manufacturing consistency and safety.

The transition from research-grade to clinical and commercial manufacturing can further complicate material selection. Some materials used during early process development may not be available at the grades or quantities required for later manufacturing. Supplier qualification, verification of critical material attributes, and assessment of residual process materials therefore become important components of process development. Addressing these requirements early may reduce the need for disruptive changes as manufacturing advances.

The need for reproducibility also extends to changes in equipment, manufacturing location, and production campaigns. The FDA's 2023 draft guidance on manufacturing changes and comparability for cellular and gene therapy products recommends assessing whether process changes affect product quality.2 For stem-cell–derived islets, comparability assessments may need to examine differentiation outcomes, cellular composition, and functional performance, rather than relying on equivalent production volumes alone. The guidance remains a draft and does not establish binding requirements.

The available bioreactor studies provide encouraging evidence that islet production can be expanded while preserving important functional properties. However, experimental improvements in yield do not establish the reproducibility, operating scale, or economic performance required for commercial manufacturing. Further progress will depend on demonstrating that increased production consistently delivers qualified therapeutic material across manufacturing batches.

From Bioreactor to Transplant-Ready Product

Even when a manufacturing process produces sufficient quantities of stem-cell-derived islets, developers face a fundamental analytical question: how can they establish that one batch of living, heterogeneous cells will perform comparably to another? Addressing that question requires more than demonstrating that the cells possess expected biological markers. Developers must identify measurable attributes that reflect the product's intended activity and establish methods capable of detecting meaningful differences in quality.

For stem-cell–derived islets, product characterization encompasses several distinct attributes. Identity testing establishes whether the intended cellular populations are present, while purity testing addresses unwanted or residual cell types. Viability measurements assess cell survival, and genomic characterization helps identify potential safety concerns associated with the starting material and differentiation process. Functional assays provide evidence of the cells' ability to perform their intended biological role. These measurements are complementary because no individual attribute fully describes the quality of the resulting product.

Potency is particularly important because the intended therapeutic effect depends on glucose-responsive insulin secretion. Glucose-stimulated insulin secretion assays can demonstrate aspects of that activity, but their results must be interpreted in the context of the cellular population and testing conditions. The presence of insulin-producing cells, even in substantial numbers, cannot independently establish that a product possesses the functional characteristics required for clinical performance.

A further challenge is determining how well laboratory measurements predict therapeutic behavior after transplantation. In vitro assays can characterize insulin secretion and cellular responses under controlled conditions, while appropriate in vivo studies provide information about engraftment, functional onset, and the persistence of activity. The selection of complementary methods is important for establishing a meaningful relationship between product attributes and biological performance, without assuming that every characterization method must become a routine lot-release assay.

In November 2026, the FDA issued final guidance on potency assurance for cellular and gene therapy products, recommending a science- and risk-based strategy incorporating process design, manufacturing controls, material controls, in-process testing, and lot-release potency assays.10 The guidance emphasizes that potency assurance depends on control of manufacturing operations as well as testing finished material.

For islet cell products, this approach places particular importance on the relationship between differentiation conditions and the resulting cellular characteristics. Monitoring the emergence of intended cell populations, assessing the persistence of unwanted cells, and evaluating functional characteristics at appropriate stages can help identify variability before it affects the finished product. These data can inform the selection of critical quality attributes, analytical methods, and acceptance criteria.

The appropriate analytical strategy also depends on the therapeutic configuration. Stem-cell–derived products require particular attention to differentiation-related impurities and genomic stability. Gene-edited products introduce additional considerations associated with the engineered cells, while encapsulated products require evaluation of biomaterial properties, structural integrity, biocompatibility, and functional performance. For encapsulated therapies, testing cells independently may provide insufficient information about the safety or activity of the complete implanted product.

Preservation and distribution extend these requirements beyond the bioreactor. Stem-cell–derived islets consist of living, multicellular aggregates whose function depends on maintaining cellular viability and biological activity. Reliable cryopreservation could support product banking, distribution, and coordination of clinical administration, but freezing and thawing introduce stresses that may compromise the resulting cells.

A 2026 review by Barsukova and colleagues examined challenges associated with cryopreserving stem-cell-derived aggregates, including cryoprotectant loading and unloading, cooling and warming rates, and aggregate microstructure.11 Because islet aggregates contain multiple interacting cells, preservation conditions must account for the behavior of the multicellular structure rather than assuming that methods suitable for isolated cells will provide equivalent results.

Post-thaw assessment must also extend beyond survival alone. A product may retain viable cells while exhibiting changes in functional characteristics that affect its suitability for transplantation. Developers therefore need preservation strategies and testing methods that demonstrate retention of relevant quality attributes through storage, preparation, and administration. Establishing these capabilities could support more flexible manufacturing and clinical delivery while providing evidence that the biological characteristics achieved during differentiation remain intact when the product reaches the patient .

What Will Determine the Next Generation of Cell Replacement Therapies?

The next phase of diabetes cell replacement development will require evidence that the clinical benefits observed in early studies can be sustained, reproduced, and delivered through practical therapeutic platforms. A therapy that demonstrates durable function but requires substantial immunosuppression may remain appropriate for a narrower patient population. An immune-protected product that avoids systemic treatment but provides insufficient insulin secretion may offer limited clinical benefit. Similarly, increased manufacturing capacity will have limited practical value unless the resulting cells consistently meet the requirements for therapeutic use. Clinical durability, immune protection, and manufacturing reproducibility must therefore be evaluated as connected dimensions of therapeutic performance.

The restoration of endogenous insulin secretion in clinical studies has provided a compelling foundation for further development. The evidence needed to advance the field will differ among encapsulated, gene-edited, and other cell replacement platforms, but the underlying requirement is consistent: developers must establish that therapeutic function can be maintained while the cells are protected, manufactured, characterized, and delivered reliably. The next generation of diabetes cell replacement therapies will be defined by the ability to make restored insulin secretion durable, immune protection clinically acceptable, and living-cell manufacturing sufficiently consistent to support broader patient access.

References

1. Reichman, Trevor W, et al. "Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes." New England Journal of Medicine. 393: 858–868 (2025).

2. "FDA Approves First Cellular Therapy to Treat Patients with Type 1 Diabetes." U.S. Food and Drug Administration. 28 Jun. 2023.

3. Press, Chengyuan, et al. "Allogeneic Islet Products for Type 1 Diabetes: Navigating Nonclinical and Manufacturing Regulatory Expectations." Stem Cell Reports. 21: 102998 (2026).

4. Verhoeff, Kevin, et al. "Scalable Bioreactor-Based Suspension Approach to Generate Stem Cell-Derived Islets From Healthy Donor-Derived iPSCs." Transplantation. 109: e22–e35 (2025). https://doi.org/10.1097/TP.0000000000005108

5. Maghera, Jasmine, et al. "The Comparative Cell Physiology of Stem Cell-Derived and Primary Human β Cells." Nature Reviews Endocrinology. 4 Sep. 2026.

6. "Vertex Announces Program Updates for Type 1 Diabetes Portfolio." Vertex Pharmaceuticals. 28 Mar. 2025.

7. Carlsson, Per-Ola, et al. "Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression." New England Journal of Medicine. 393: 887–894 (2025).

8. Carlsson, Per-Ola, et al. "Long-Term Survival of Hypoimmune Allogeneic Islets without Immunosuppression." New England Journal of Medicine. 395: 825–827 (2026).

9. Dadheech, Nidheesh, et al. "Scale Up Manufacturing Approach for Production of Human Induced Pluripotent Stem Cell-Derived Islets Using Vertical Wheel® Bioreactors." npj Regenerative Medicine. 10: 24 (2025).

10. Guidance for Industry: Potency Assurance for Cellular and Gene Therapy Products. U.S. Food and Drug Administration. 2 Nov. 2026.

11. Barsukova, Anita Dey, et al. "Cryopreservation of Stem Cell-Derived Aggregates for Type 1 Diabetes Cell Therapy: Considerations and Challenges." Journal of Controlled Release. 395: 114914 (2026).

STAGING